Insmed has reiterated its target of at least $1 billion in BRINSUPRI revenue by 2026 and is aiming for ARIKAYCE label expansion in the first half of 2027.

Insmed (INSM) is anticipated to see significant upside in 2026, driven by a potential $1.3 billion increase in Arikayce sales, leading Roth/MKM to initiate a 'Buy' rating.

Insmed's stock has seen a rise after the company announced positive late-stage trial results for its drug Arikayce, which is used to treat lung infections.

Insmed Incorporated provided a summary of its Q4 2025 earnings call.

Insmed Incorporated has reported gains attributed to its lead product, ARIKAYCE, indicating positive performance for the company.